A Trial Evaluating TG4050 in Ovarian Carcinoma.
This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.
Ovarian Carcinoma|Fallopian Tube Cancer|Peritoneal Carcinoma
DRUG: TG4050
Safety and tolerability (Adverse Event reported per CTCAE v5), Incidence of Adverse Event reported per CTCAE v5, At each study visit up to final safety follow up visit: every week for the first 6 weeks and then every 3 weeks
Best overall response rate as assessed by the Gynecological Cancer Intergroup (GCIC) Carbohydrate Antigen 125 (CA-125) criteria, Percentage of patients with a minimum 50% reduction in CA-125 serum levels lasting for 28 days relative to pre-treatment CA-125 serum level per the GCIC criteria., Every 3 weeks|Best Overall Tumor Response Rate, Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria over the the total number of patients evaluable., Within 21 days of treatment initiation and then every 9 weeks|Rate of patients with immune response, Percentage of patients who achieve an immune response established by the detection of antigen-specific T cell., Days 64, 85 and 211
This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.